Champions Oncology, Inc.

CSBR Healthcare Biotechnology

Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025. In the quarter to July 2026, revenue grew 8.84%, EPS was flat and free cash flow fell 198.7%, each against the same quarter a year earlier.

4.70 0.09 −1.88%
Market cap
$66.7M
P/E
0.0×
Fwd P/E
−41.6×
Dividend yield
—
F-score
3/9
Altman Z
−0.02
Beneish M
−1.80
Dividend safety
n/a
Jul '26 Apr '26 Jan '26 Oct '25 Older periods
Piotroski F-Score
3 3 3 8

+8 more TTM periods

ROE
(28.38%) (29.97%) (46.96%) 100.24%
ROA
(3.56%) (3.96%) (7.83%) 8.89%
ROIC
(626.23%) 0.00% 0.00% 0.00%
Return on Tangible Assets
(26.09%) (41.62%) (71.96%) 78.36%
Average Days of Receivables
81.84 80.94 76.01 72.09
Free Cash Flow per Share
(0.44) (0.36) 0.28 0.41
Free Cash Flow
(6.11) (5.01) 3.84 5.64
Other line items

Show all line items

Columns are period end dates